Introduction
============

Cardiovascular disorder comprises various diseases affecting the heart and blood vessels, resulting in different comorbidities and life-threatening complications. Cardiovascular disease (CVD) is causing worldwide concern because of the rising prevalence and consequence of morbidity and mortality rate with huge economic burden.[@b1-vhrm-13-143] The rise in CVDs is being witnessed globally among various cultures and ethnic groups because of epidemiological shifts.[@b2-vhrm-13-143] In low-income countries also, CVDs are among the emerging health problems as major contributors to the disease burden.[@b3-vhrm-13-143] Among sociodemographic variables, age is an important predisposing factor for chronic disorders, CVDs in particular. Factors related to diet and sedentary lifestyle also contribute to increased occurrence of CVDs.[@b4-vhrm-13-143]

In the past 20--30 years, the emerging CVD epidemic in developing countries has not been given enough attention, nor adequate public health response, globally and in the countries themselves. The fact that developing countries share a higher proportion of CVD burden than developed nations is not recognized well.[@b5-vhrm-13-143] CVD is the biggest cause of death worldwide and is estimated to remain the leading cause of mortality. An estimated 17.5 million people died from CVD globally, accounting for 30% of all deaths, in 2005. The majority of these deaths occurred in the developing countries.[@b3-vhrm-13-143]

According to a systematic review, CVD (24%), cancer (10%), diabetes (5%), and chronic obstructive pulmonary diseases (3%) were found to be important causes of death in different parts of Ethiopia. Predisposing factors such as rheumatic heart disease, khat chewing, obesity, and physical inactivity were responsible for CVD burden especially in the urban Ethiopian population.[@b6-vhrm-13-143]--[@b8-vhrm-13-143] In general, despite the increasing threat of noncommunicable diseases (NCDs), communicable diseases are still the main causes of admission to medical wards in developing countries, while NCDs are leading in the developed world.[@b9-vhrm-13-143],[@b10-vhrm-13-143] CVDs account for a significant number of patient visits, though the burden by etiologic type varies in different regions of the globe. This is dependent on epidemiologic transition and the various stages in its development that a country has to undergo.[@b11-vhrm-13-143] The pattern of prevalence of CVDs is distinctly different in sub-Saharan Africa (SSA), compared to the rest of the world, since infectious and inflammatory diseases are relatively more common.[@b12-vhrm-13-143]

Although infectious diseases are still the leading causes of morbidity and hospital admission in developing countries like Ethiopia, in recent decades there has been significant epidemiological transition to NCDs.[@b9-vhrm-13-143] In turn, the clinical pattern of the diseases and the shifts need to be characterized. CVDs are responsible for the majority of morbidity and mortality among NCDs in Ethiopia. Despite the rise of NCDs, the country's full attention was in combating the communicable diseases such as HIV, tuberculosis, and malaria.[@b11-vhrm-13-143],[@b13-vhrm-13-143]

Similar to most SSA countries, there is a lack of data on the patterns and clinical characteristics of CVD in Ethiopia. This is due to the lack of study done about CVD patterns in recent years despite the emergence of NCDs in the developing world. Hence, this study was conducted in northwestern Ethiopia, one of the low-income countries. It aimed to explain the pattern and characteristics of CVDs and suggest on the future pattern of CVDs by assessing clinical characteristics and associated factors among patients with CVDs.

Methods
=======

Patients and settings
---------------------

The study was conducted in Gondar University Referral Hospital (GURH), which is located in Gondar town, 738 km from Addis Ababa, the capital city of Ethiopia. The outpatient department of the hospital has specific clinics where patients with chronic diseases and CVDs are followed-up. The clinics are staffed with internists, residents, and general practitioners with expertise in specific chronic disease patient follow-up. The source population for the study included medical records of all patients diagnosed with a CVD. Medical records that had the required sociodemographic information and medical records during the study period were included in the study. Incomplete medical records were excluded from the study.

Study design and study period
-----------------------------

A retrospective cross-sectional study design, based on review of medical records of patients, was followed in this study. The medical records of patients who started their follow-up at the chronic illness clinics between October 2010 and October 2015 were included in the study. Data collection was conducted from August 2015 to December 2015.

Data collection procedure
-------------------------

The data were collected by four trained clinical pharmacists by using a structured pretested checklist. The checklist included basic demographic data including age, sex, residence, and the year in which follow-up started. Records on chief complaint, signs and symptoms, echocardiography results (if available), last follow-up assessment, and summary of important laboratory findings (such as serum electrolytes and organ function tests) were also included. The data collection tool was developed in consultation with senior clinical researchers at GURH, and it was pretested for its validity before the actual data collection commenced.

Diagnosis, prognosis, as well as treatment response information were taken from the evaluation in the last follow-up of patients in the study. Standard laboratory reference range values from clinical chemistry textbooks and *Harrison's Principle of Internal Medicine* were used, to classify each laboratory test result as low, normal, or high ([Table 3](#t3-vhrm-13-143){ref-type="table"}).[@b14-vhrm-13-143],[@b15-vhrm-13-143] Medical records of study participants were selected by their chart number, from the chronic illness clinic CVD patient registration book. Based on this, individual medical records were traced, and pertinent data were filled into the data collection format.

Data entry and analysis
-----------------------

The data collected were entered into and analyzed by using SPSS for Windows version 20.0. In the analysis, descriptive statistics, chi-square tests, and binary logistic regression were done. In the analysis, 95% confidence interval (CI) and *P*-value \<0.05 were used as cutoff points, to determine the statistical significance of the tests of associations of different variables with CVDs.

Data quality control
--------------------

The measures taken to ensure data quality included pre-testing of the data collection instrument to check for consistency and validity, training of data collectors, supervision by the principal investigator, and checking completeness and internal consistency of data during and after data collection, as well as entry. Ethical clearance was obtained from the ethical review committee of the University of Gondar. In addition, a letter of permission was obtained from the medical director of GURH. However, patient consent was exempted by the ethical review committee of the University of Gondar, as individual patient data were kept anonymous and confidential by ensuring data taken from patient charts did not include any personal identifiers and was used only for the purpose of this study.

Definitions of terms and operational definitions
------------------------------------------------

For the purpose of this study, CVDs were categorized as diagnosed by the physician and basic diagnostic parameters with standard definitions. On the basis of this, the CVD was categorized as hypertension when blood pressure was ≥140/90 mmHg, congestive heart failure (CHF) if there was presence of two or more of the adapted Framingham criteria or presence of one major criteria and two minor criteria, and rheumatic heart disease if there was presence of two major modified Jones criteria or one major and two minor criteria. Dyslipidemia diagnosis was determined by patient lipid profile of cholesterol and triglycerides exceeding 200 and 150 mg/dL, respectively.[@b16-vhrm-13-143],[@b17-vhrm-13-143]

Patients' clinical condition was classified as good, fair, and poor based on the following definitions.

Good: patients had better prognosis both clinically and in laboratory parameters (signs and symptoms resolved, blood pressure, cholesterol, and other diagnostic parameters far better than initial diagnosis and the previous follow-up).

Fair: there was improvement from state at the previous visit and moderate change in laboratory parameters but not at the level they could be.

Poor: there was no improvement at all or patient conditions might have become worse.

Improved: in this study, it signifies an assessment rated as fair or good on the last follow-up.

The terms cardiovascular outcome and CVD improvement were used interchangeably in this study.

Results
=======

Socio-demographic and related characteristics
---------------------------------------------

Of 1105 patient medical records, 243 were excluded because of incompleteness and the remaining 862 were included in the final analysis. Of these, approximately two thirds (65%) were female patients. Similarly, two thirds (65.2%) of the patients were \>50 years of age; the age group 50--59 years constituted nearly a quarter (23.6%) of CVDs that had been documented. The majority (62.7%) of patients were from urban areas. More than half (55%) of the patients did not have a documented comorbidity in the whole follow-up period from first diagnosis to the last follow-up. More than one quarter of the CVD patients started follow-up in 2015. Considering prognosis, nearly two thirds (63.5%) of the patients had good improvement on their last follow-up, whereas 14.4% had poor assessment of their CVD ([Table 1](#t1-vhrm-13-143){ref-type="table"}). The most frequent comorbidity reported was diabetes mellitus in 9% of the patients, followed by thyroid-related disorders (7%) and peptic ulcer disease/dyspepsia (6%) ([Figure 1](#f1-vhrm-13-143){ref-type="fig"}).

More than a third (37.7%) of patients diagnosed with CVD for the first time came to hospital because of chief complaints of headache, followed by dyspnea (11.5%), cough (11.1%), body swelling (10.2%), easy fatigability (8.1%), and palpitations (6.8%) ([Figure 2](#f2-vhrm-13-143){ref-type="fig"}).

Clinical presentation of CVD patients
-------------------------------------

More than half of the CVD patients complained of headache at least once in their course of follow-up visits, followed by dyspnea in approximately half of the patients. Orthopnea, easy fatigability, palpitations, and cough were also frequently reported signs and symptoms in more than one third of the CVD patients ([Table 2](#t2-vhrm-13-143){ref-type="table"}).

Among the patients who had an electrolyte test, approximately three quarters of them had their results within the normal range. One third of the patients, who underwent serum cholesterol test, had hypercholesterolemia. More than 29% of the patients had high serum creatinine and blood urea nitrogen (BUN) level ([Table 3](#t3-vhrm-13-143){ref-type="table"}). From the total of 505 CVD patients, 31.5% of them had reduced ejection fraction from the echocardiography report ([Table 5](#t5-vhrm-13-143){ref-type="table"}).

CVD distribution
----------------

Of the 862 patients in the study, 541 (62.76%) were hypertensive, followed by patients with heart failure (HF) 206 (23.9%), hypertensive heart disease 132 (15.3%), and rheumatic heart disease 102 (11.8%). Regarding sex distribution, females constituted higher proportions in all CVDs except in pulmonary hypertension and congenital heart disease. A chi-square test showed that females (53.1%) had a statistically significant (*P*=0.042) higher proportion of stroke than males. Statistically significant differences in CVDs were also found in patients from rural areas contributing higher proportions of HF (55.8%), arrhythmia (52.1%), rheumatic valvular heart disease (RVHD) (52%), dilated cardiomyopathy (DCMP) (62.7%), cor pulmonale (84%), degenerative valvular heart disease (DVHD) (60.2%), and pulmonary hypertension (63.6%) disease patterns (*P*\<0.01). Patients from urban areas had higher proportions of dyslipidemia (85.7%), hypertension (72.8%), and ischemic heart disease (IHD) (73.2%) ([Table 4](#t4-vhrm-13-143){ref-type="table"}). Of 102 RVHD patients with echocardiograph reports, 57 (55.8%), 61 (59.8%), 34 (33.3%), and 18 (17.6%) had mitral stenosis (MS), mitral regurgitation (MR), aortic regurgitations, and combined MS and MR, respectively ([Table 5](#t5-vhrm-13-143){ref-type="table"}).

Factors associated with poor CVD improvement
--------------------------------------------

A binary logistic regression analysis revealed that rural residency was more likely to be associated with poor CVD improvement (crude odds ratio (COR)=1.306(1.026--2.166), adjusted odds ratio (AOR) =1.272(1.017--2.030). Less than or equal to 1 month follow-up was associated with less risk of poor CVD improvement (COR =0.561(0.236--0.759), AOR =0.502(0.213--0.741) and COR =0.691(0.451--0.895), AOR =0.623(0.331--0.842), respectively). Patients with comorbid conditions were 1.5 times more likely to have poor cardiovascular outcome/improvement (COR =1.813(1.279--2.782), AOR =1.551(1.177--2.705)) ([Table 6](#t6-vhrm-13-143){ref-type="table"}).

Discussion
==========

Nowadays, there is a global epidemiological transition in the developing countries through the changing disease pattern from infectious diseases to NCDs. This study was conducted to evaluate the pattern of CVDs in an Ethiopian university referral hospital. It provided some insight into the current epidemiological pattern of cardiovascular disorders in the country. To the best of the authors' knowledge, the pattern of CVDs in GURH was assessed two decades ago and it may not give the right current picture of CVDs and of that in the near future. The study reported that rheumatic heart disease was responsible for 42% of CVDs followed by hypertension in 38.1% of CVDs.[@b13-vhrm-13-143] The most prevalent CVD in the present study was hypertension (62.3%), followed by HF (23.9%). This was similar to most of the studies that found that hypertension is the dominant morbidity and is responsible for most of the cardiovascular events among adults with CVDs.[@b18-vhrm-13-143]

The leading cardiac diseases among the patients included hypertensive heart disease, rheumatic heart disease, arrhythmia, degenerative heart disease, DCMP, and IHD in decreasing order. This finding was not in agreement with studies conducted in northern Malawi, Addis Ababa, Jimma, and the same institution two decades ago, which concluded that rheumatic heart disease was the leading cause of heart disease followed by hypertensive heart disease.[@b3-vhrm-13-143],[@b11-vhrm-13-143],[@b13-vhrm-13-143],[@b19-vhrm-13-143],[@b20-vhrm-13-143] The leading cardiac disease etiologies identified by the study performed in Bangladesh were IHD, HF, and chronic RVHD.[@b21-vhrm-13-143] In this study, hypertensive heart disease had surpassed rheumatic heart disease as the leading heart disease. This might be due to the increasing prevalence of hypertension, as supported by the high proportion of hypertension of approximately two thirds (62.3%) of CVDs found in this study. It could also partly be justified by the reduction of rheumatic heart disease, due to the early treatment of respiratory tract infection and early detection of rheumatic fever because of better access to health care in Ethiopia.[@b22-vhrm-13-143]

Headache was the most common complaint during the first visits. This might be attributed to the high prevalence of hypertension among CVDs in the study, which manifests with the characteristic occipital type of morning time headache, which is a reason for patients to visit health institutions and check their blood pressure. Differential diagnoses such as malignant pheochromocytoma, hypertensive crisis including hypertensive encephalopathy and eclampsia could contribute to this chief presentation.[@b23-vhrm-13-143]

Diabetes mellitus was found to be a more prevalent comorbid condition in cardiovascular patients of this study. Similar findings were demonstrated by Shukrala et al in an Eastern Ethiopia hospital on hypertensive patients, where diabetes was a comorbidity and was predominant.[@b24-vhrm-13-143],[@b25-vhrm-13-143] Two thirds of the patients were \>50 years of age, and the risk of developing CVD increases with age.[@b12-vhrm-13-143]

In this study, 68.5% of CVD patients had preserved ejection fraction based on the documented echocardiography reports. This was much higher than the proportion reported among CHF patients (52.7%) in the same study setup.[@b26-vhrm-13-143] It is reasonable that ejection fraction is reduced more in HF patients than the general cardiovascular patient population.[@b27-vhrm-13-143] The finding in this study was also in agreement, with little variation, with studies done in Spain (72.2%) and Japan (72%).[@b28-vhrm-13-143] The disparity between these studies and the present study might be credited to the difference in geographic location, sample size, age of the patients, race, and cutoff values for ejection fraction within each study study.[@b29-vhrm-13-143]

Approximately a third of the patients, among those tested, had high serum creatinine and BUN levels. This suggests that CVD may cause kidney damage and might result in elevation of creatinine and BUN; however, it cannot be generalized based on this study. But a study done at a nephrology clinic in Uganda suggested that CVDs were the primary risk factors for end-stage renal diseases, morbidity, and mortality of renal patients.[@b30-vhrm-13-143]

Chi-square test revealed that hypertension (72.8%), dyslipidemia (85.7%), and IHD (73.2%) were found to be highly associated with urban residency. Lifestyle changes and expansion of urbanization in developing countries might have contributed to this association. Sedentary life is more common in urban areas because more of the residents work in offices and other jobs which do not need physical effort. Besides this, dietary habits are different in rural areas.[@b31-vhrm-13-143] As people in rural Ethiopia are daily laborers and farmers who spend their days in physical labor to earn a living, this contributes to lower cardiovascular disorders, dyslipidemia, hypertension, and IHD. In contrast, HF, arrhythmia, stroke, DCMP, RVHD, DVHD, and cor pulmonale were higher in rural areas than urban areas. This could be due to difficulties faced by people in rural areas to make the necessary follow-ups at health institutions; rather they come after the disease becomes more advanced and severe.[@b32-vhrm-13-143]

Most of the rheumatic valvular disease patients had mitral involvement, MS (55.8%), MR (59.8%) followed by aortic involvement aortic regurgitation (33.3%). Unlike this finding, a study done in the cardiac clinic of Jimma University Hospital indicated 55% and 25% of cases of MS and MR, respectively. This might be attributed to the increment of other valvular involvement. The impact of rheumatic heart disease on a patient's loss of productivity is significant, because functionality cannot be reversed by treatment only, and the effective management for valvular heart disease is surgical intervention. Surgical repair and valvular intervention is not routinely practiced in Ethiopian hospitals and other developing countries because of the economic and technological barriers.[@b11-vhrm-13-143],[@b13-vhrm-13-143]

The binary logistic regression test indicated that living in rural areas was found to be associated with poor improvement of CVDs. This might be because of poor medication adherence and loss to scheduled follow-up due to various barriers of education (illiteracy) and inaccessibility of the health facility.[@b12-vhrm-13-143],[@b32-vhrm-13-143] Frequent appointments for follow-up was associated with CVD improvement. This might be due to the closer follow-up with physicians and frequent evaluation of adherence, which result in more improvement. Having different morbidity was associated with poor control of CVDs and risks for multiple drug use to manage the comorbidity, which might affect the disease improvement.[@b24-vhrm-13-143]

Limitations of the study
========================

The number of visits and the course of the disease at each appointment from initial diagnosis to the last follow-up were not studied explicitly; therefore, it was difficult to consider its contribution for the final cardiovascular outcome assessment and to the disease prognosis. It was studied retrospectively based solely on the secondary data; and it may not give all the required data at prospective follow-up.

In addition to this, this is a single-centered hospital-based study; hence, it may not be representative to the population CVD distribution, unlike population-based studies. Despite this limitation, this is the first study to our knowledge in our country and institution conducted to assess the CVD pattern, clinical characteristics, and associated factors for the disease outcome. We believe that it will provide insights into epidemiological transition of CVDs and a baseline for large population-based prospective research studies.

Conclusion
==========

Hypertension was found to be the most frequent CVD followed by HF and takes the greatest share of CVD burden. Hypertensive heart disease, RVHD, arrhythmia, DVHD, and DCMP were the top five cardiac diseases in decreasing order of frequency. Most of the patients had improved outcome on their last follow-up, but patients from rural areas and those with comorbid conditions had higher likelihood of poor cardiovascular outcome. Clinicians, public health experts, policy makers, and health care administrators should give attention to the changing patterns of CVDs in developing countries and put emphasis on public health strategies of prevention, early detection, and management. Large community-based studies are recommended for better population representativeness and generalization.
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![Comorbidities other than cardiovascular disease in the chronic illness clinic of Gondar University Referral Hospital, October 2010 to October 2015.\
**Abbreviations:** PUD, peptic ulcer disease; COPD, Chronic obstructive pulmonary disease; CKD, chronic kidney disease; RVI, retroviral infection.](vhrm-13-143Fig1){#f1-vhrm-13-143}
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###### 

Sociodemographic and related characteristics of the cardiovascular patients, Gondar 2015

  Variables                        Frequency (%)
  -------------------------------- ---------------
  **Sex**                          
   Male                            302 (35)
   Female                          560 (65)
  **Age (years)**                  
   10--19                          21 (2.4)
   20--29                          58 (6.7)
   30--39                          89 (10.3)
   40--49                          133 (15.4)
   50--59                          203 (23.6)
   60--69                          198 (23.1)
   70--79                          125 (14.5)
   ≥80                             35 (4)
  **Residence**                    
   Rural                           322 (37.3)
   Urban                           540 (62.7)
  **Year of registration**         
   2010                            39 (4.5)
   2011                            114 (13.2)
   2012                            129 (15)
   2013                            217 (25.2)
   2014                            135 (15.7)
   2015                            228 (26.5)
  **Time of follow-up**            
   \<1 month                       114 (13.2)
   1 month                         224 (26)
   2 months                        288 (33.4)
   3 months                        236 (27.4)
  **Medical status of patients**   
   Good                            547 (63.46)
   Fair                            191 (22.16)
   Poor                            124 (14.38)

###### 

Clinical presentation of cardiovascular disease patients who had follow-up at Gondar University Referral Hospital during the period from October 2010 to October 2015

  Signs and symptoms             Yes, n (%)   No, n (%)
  ------------------------------ ------------ ------------
  Headache                       439 (50.9)   423 (49.1)
  Dizziness                      56 (6.5)     806 (93.5)
  Vertigo                        70 (8)       792 (92)
  Tinnitus                       50 (5.8)     812 (94.2)
  Cough                          283 (32.8)   579 (67.2)
  Weakness of extremities        62 (7.2)     800 (92.8)
  Blurred vision                 162 (18.8)   700 (81.2)
  Chest pain                     237 (27.5)   625 (72.5)
  Light headedness               23 (2.7)     839 (97.3)
  Dyspnea                        416 (48.3)   446 (51.7)
  Orthopnea                      336 (39)     526 (61)
  Easy fatigability              332 (38.5)   530 (61.5)
  Palpitations                   330 (38.3)   532 (61.7)
  Facial puffiness               52 (6)       810 (94)
  Body/leg swelling              248 (28.8)   614 (71.2)
  Paroxysmal nocturnal dyspnea   120 (13.9)   742 (86.9)
  Nasal bleeding                 3 (0.3)      859 (99.7)
  Loss of consciousness          14 (1.6)     848 (98.4)

###### 

Laboratory characteristics of CVD patients during their first visit at GURH, 2015 (N=862)

  Laboratory parameters with standard values   Test was not done, n (%)   Test was done, n (%)   Normal, n (%)   Low, n (%)   High, n (%)
  -------------------------------------------- -------------------------- ---------------------- --------------- ------------ -------------
  Creatinine (0.6--1.1 mg/dL)                  300 (34.8)                 562 (65.2)             346 (61.6)      48 (8.5)     168 (29.9)
  BUN (7--20 mg/dL)                            352 (40.8)                 509(59.2)              319 (62.7)      39 (7.7)     151 (29.6)
  K^+^ (3.5--5 meq/L)                          597 (69.3)                 265(30.7)              190 (71.7)      52 (19.6)    23 (8.7)
  Na^+^ (135--145 meq/L)                       594 (68.9)                 268(31.1)              202 (75.4)      42 (15.7)    24 (8.9)
  Ca^+^ (2.24--2.46 meq/L)                     620 (71.9)                 242(28.1)              189 (78.1)      28 (11.6)    25 (10.3)
  SGPT (\<35 IU/L)                             376 (43.6)                 486(56.4)              369 (75.9)      na           117 (24.1)
  SGOT (\<35 IU/L)                             370 (42.9)                 492(57.1)              376 (76.4)      na           116 (23.6)
  Triglycerides (\<150 mg/dL)                  531 (61.5)                 331(38.5)              239 (72.2)      na           92 (27.8)
  Cholesterol (\<200 mg/dL)                    535 (62.1)                 327(37.9)              218 (66.7)      na           109 (33.3)

**Abbreviations:** BUN, blood urea nitrogen; CVD, cardiovascular disease; GURH, Gondar University Referral Hospital; BUN, blood urea nitrogen; na, not applicable.

###### 

Cardiovascular disorder distribution by sex and residency among patients who attended follow-up at the chronic illness clinic of Gondar University Referral Hospital during the period from October 2010 to October 2015

  Cardiovascular disorders                     Sex         *p*-value    Residence                                           *p*-value    Total N=862, n (%)                                                         
  -------------------------------------------- ----------- ------------ --------------------------------------------------- ------------ -------------------- ----------------------------------------------------- -------------
  Dyslipidemia                                 37 (40.7)   54 (59.3)    0.553                                               13 (14.3)    78 (85.7)            0.015[\*](#tfn2-vhrm-13-143){ref-type="table-fn"}     91 (10.5)
  Stroke                                       30 (46.9)   34 (53.1)    0.042[\*](#tfn2-vhrm-13-143){ref-type="table-fn"}   20 (31.2)    44 (68.8)            0.284                                                 64 (7.4)
  Heart failure                                63 (30.6)   143 (69.4)   0.122                                               115 (55.8)   91 (44.2)            0.000[\*\*](#tfn3-vhrm-13-143){ref-type="table-fn"}   206 (23.9)
  Arrhythmia                                   33 (34.4)   63 (65.6)    0.40                                                50 (52.1)    46 (47.9)            0.000[\*\*](#tfn3-vhrm-13-143){ref-type="table-fn"}   96 (11.3)
  Hypertension                                 200 (37)    341 (63)     0.14                                                147 (27.2)   394 (72.8)           0.000[\*\*](#tfn3-vhrm-13-143){ref-type="table-fn"}   541 (62.76)
  Rheumatic valvular heart disease (RVHD)      35 (34.3)   67 (65.7)    0.48                                                53 (52)      49 (48)              0.003[\*\*](#tfn3-vhrm-13-143){ref-type="table-fn"}   102 (11.8)
  Ischemic heart disease (IHD)                 16 (28.6)   40 (71.4)    0.184                                               15 (26.8)    41 (73.2)            0.098                                                 56 (6.5)
  Dilated cardiomyopathy (DCMP)                32 (40)     48 (60)      0.30                                                50 (62.5)    30 (37.5)            0.000[\*\*](#tfn3-vhrm-13-143){ref-type="table-fn"}   80 (9.3)
  Cor pulmonale                                4 (21.1)    15 (78.9)    0.196                                               16 (84.2)    3 (15.8)             0.000[\*\*](#tfn3-vhrm-13-143){ref-type="table-fn"}   19 (2.2)
  Pulmonary hypertension                       12 (54.5)   10 (45.5)    0.052                                               14 (63.6)    8 (36.4)             0.043[\*](#tfn2-vhrm-13-143){ref-type="table-fn"}     22 (2.55)
  Degenerative valvular heart disease (DVHD)   28 (30.1)   65 (69.9)    0.303                                               56 (60.2)    37 (39.8)            0.000[\*](#tfn2-vhrm-13-143){ref-type="table-fn"}     93 (10.8)
  Congenital heart disease (CHD)               2 (66.7)    1 (33.3)     0.281                                               2 (66.7)     1 (33.3)             0.297                                                 3 (0.35)
  Hypertensive heart disease (HHD)             53 (40.2)   79 (59.8)    0.181                                               52 (39.4)    80 (61.6)            0.622                                                 132 (15.3)
  Deep vein thrombosis (DVT)                   5 (45.5)    6 (54.5)     0.455                                               4 (36.4)     7 (63.6)             0.983                                                 11 (1.23)
  Pulmonary thromboembolism (PTE)              1 (50)      1 (50)       0.566                                               0 (0)        2 (100)              0.546                                                 2 (0.23)

**Notes:**

*P*\<0.05;

*P*\<0.01.

###### 

Pattern of valve(s) involvement among RVHD patients registered and who started follow-up at chronic clinic illness of Gondar University Referral Hospital, October 2010 to October 2015

  Echocardiography report on the extent of valvular involvement   Number (%)
  --------------------------------------------------------------- ------------
  MS                                                              57 (55.8)
  MR                                                              61 (59.8)
  AR                                                              34 (33.3)
  MS+MR                                                           18 (17.6)
  MS+AR                                                           11 (10.8)
  MR+TR+AR                                                        9 (8.8)
  Others                                                          15 (13.7)
  Preserved EF                                                    346 (69.5)
  Reduced EF                                                      159 (31.5)

**Notes:** Preserved EF is \>40%, reduced EF is \<40%.

**Abbreviations:** AR, aortic regurgitation; EF, ejection fraction; MS, mitral stenosis; MR, mitral regurgitation; RVHD, rheumatic valvular heart disease; TR, tricuspid regurgitation.

###### 

Factors associated with the outcome of cardiovascular patients

  Factors                    Cardiovascular outcome   Crude odds ratio (COR) (95% CI)   Adjusted odds ratio (AOR) (95% CI)   *p*-value              
  -------------------------- ------------------------ --------------------------------- ------------------------------------ ---------------------- ---------------------------------------------------
  **Sex**                                                                                                                                           
   Male                      250                      52                                1.410 (0.957--2.078)                 1.433 (0.961--2.129)   0\. 083
   Female                    488                      72                                1                                    1                      Reference
  **Age in years**                                                                                                                                  
   10--39                    142                      26                                1                                    1                      
   40--69                    460                      74                                0.879 (0.541--1.427)                 1.079 (0.583--1.995)   0.601
   ≥70                       136                      24                                0.971 (0.531--1.774)                 0.981 (0.581--1.638)   0.924
  **Residence**                                                                                                                                     
   Rural                     269                      53                                1.306 (1.026--2.166)                 1.272 (1.017--2.030)   0.041[\*](#tfn6-vhrm-13-143){ref-type="table-fn"}
   Urban                     469                      71                                1                                    1                      Reference
  **Time of follow-up**                                                                                                                             
   \<1 month                 95                       19                                0.561 (0.236--0.759)                 0.502 (0.213--0.741)   0.044[\*](#tfn6-vhrm-13-143){ref-type="table-fn"}
   1 month                   196                      28                                0.691 (0.451--0.895)                 0.623 (0.331--0.842)   0.039[\*](#tfn6-vhrm-13-143){ref-type="table-fn"}
   2 months                  242                      46                                0.751 (0.365--1.289)                 0.749 (0.348--1.156)   0.35
   3 months                  205                      31                                1                                    1                      Reference
  **Comorbidty**                                                                                                                                    
   No                        404                      70                                1                                    1                      Reference
   Yes                       334                      54                                1.813 (1.279--2.782)                 1.551 (1.177--2.705)   0.02[\*](#tfn6-vhrm-13-143){ref-type="table-fn"}
  **Year of registration**                                                                                                                          
   2010                      37                       2                                 0.298 (0.069--1.293)                 0.315 (0.072--1.378)   0.106
   2011                      94                       20                                1.173 (0.643--2.142)                 1.376 (0.739--2.561)   0.603
   2012                      118                      11                                0.514 (0.251--1.051)                 0.565 (0.274--1.162)   0.068
   2013                      180                      37                                1.133 (0.684--1.878)                 1.189 (0.174--1.980)   0.627
   2014                      116                      19                                0.903 (0.494--1.653)                 0.966 (0.524--1.781)   0.741
   2015                      193                      35                                1                                    1                      Reference

**Note:**

*P*\<0.05.
